Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd. (KMDA) will release financial results for the third quarter and nine months ended September 30, 2026, before U.S. markets open on November 9, 2026. Management will host a conference call at 8:30 a.m. Eastern Time that day to discuss the results and answer questions.
Kamada Ltd. announced commercial launches in Israel of Ustekinumab-Kamada and Enoxaparin-Kamada, adding to its two existing biosimilars. All four products were approved and launched as interchangeable with their reference biologic products. The company expects at least two more biosimilars to become commercially available during 2027.
Kamada anticipates its existing commercial biosimilar portfolio will generate approximately $4 million in sales in 2026 and approximately $10 million in 2028. By 2030, it expects the portfolio to include at least 12 marketed products licensed from six international biosimilar companies, commercialized in Israel and the Middle East and North Africa region, and to generate approximately $20 million-$25 million in annual revenue.
Kamada Ltd. responded to SEC staff comments on its Form 20-F for the fiscal year ended December 31, 2025. The company stated that it did not capitalize costs related to inventory produced for commercial sale before regulatory approval in the fiscal years ended December 31, 2025, and December 31, 2024. Kamada intends to revise future filings to describe when economic benefits may be considered probable for capitalization of pre-approval inventory costs and, to the extent material, the types of costs that may be capitalized.
KAMADA LTD director Lilach Asher-Topilsky reported three indirect employee stock-option entries held by a trustee under the company's 2011 Share Award Plan. The options cover 26,500 ordinary shares at a $7.29 exercise price, 30,000 at $5.88 and 30,000 at $7.26; the exercise prices were adjusted in connection with a special cash dividend declared August 17, 2026, with a record date of August 27, 2026. The options vest in four equal installments of 25% on each grant-date anniversary and are exercisable for 10 years after grant.
Kamada Ltd. (KMDA) reports three indirect employee stock option acquisition entries for Ishay Davidi, a director and 10% owner, dated August 27, 2026. The options are held by a trustee under the company's 2011 Share Award Plan and cover 26,500 ordinary shares at a $7.29 exercise price, 30,000 at $5.88, and 30,000 at $7.26. Footnotes state these options had been reported previously and their exercise prices were adjusted in connection with the special cash dividend declared August 17, 2026, with an August 27, 2026 record date. The exercise prices are presented in U.S. dollars using the NIS/USD exchange rate published by the Bank of Israel as of September 29, 2026.
Kamada Ltd (KMDA) reported two option awards associated with director Uri Botzer on August 27, 2026, each covering 30,000 ordinary shares and held by a trustee under the company’s 2011 Share Award Plan. The respective exercise prices are $5.23 and $7.26 per share. The exercise prices were adjusted in connection with a special cash dividend declared August 17, 2026, with an August 27, 2026 record date; the stated dollar prices use the Bank of Israel NIS/USD exchange rate published as of September 29, 2026.
KAMADA LTD (KMDA) reports two employee stock-option awards for London Amir, Chief Executive Officer, each covering 400,000 ordinary shares and dated August 27, 2026. The options are held by a trustee under the company's 2011 Share Award Plan, with exercise prices of $5.99 and $7.44 per share. They vest in four equal installments, with 25% vesting on each anniversary of the grant date. The exercise prices were adjusted in connection with the special cash dividend declared by the board on August 17, 2026. Prices are presented in U.S. dollars based on the Bank of Israel NIS/USD exchange rate as of September 22, 2026.
KAMADA LTD's VP, BD and Strategic Programs, Boris Gorelik, reported a grant of 15,000 employee stock options on August 27, 2026. The options cover ordinary shares and are held by a trustee under the Company's 2011 Share Award Plan. The reported exercise price is $9.41 per share, presented in U.S. dollars using the Bank of Israel exchange rate as of September 22, 2026.
The options vest in four equal installments, with 25% vesting on each of the four anniversaries of the grant date. Their exercise price was adjusted from $9.57 in connection with a special cash dividend declared August 17, 2026, with an August 27, 2026 record date.
KAMADA LTD director Lilach Payorski reported two indirect employee stock-option acquisitions on August 27, 2026, each covering 30,000 ordinary shares and held by a trustee under the company’s 2011 Share Award Plan. The listed exercise prices are $5.99 and $7.38 per share, adjusted in connection with a special cash dividend declared August 17, 2026. The prices are presented in USD using the exchange rate as of September 22, 2026. The options vest over four years in four equal installments and are exercisable for 10 years following the grant date.
KAMADA LTD VP Human Resources Reshef Liron reported grants on August 27, 2026, of employee stock options covering 40,000 and 60,000 ordinary shares. The options are held by a trustee under the company’s 2011 Share Award Plan. Their reported USD exercise prices are $5.12 and $7.44 per share, adjusted in connection with a special cash dividend distribution declared August 17, 2026, with a record date of August 27, 2026. Each award vests in four equal installments, with 25% vesting on each anniversary of its grant date.